AAD 2026Abstract 71012
Post-Marketing Safety Profile of Topical Ruxolitinib
A FAERS Pharmacovigilance Study with Comparative Insights from Oral Upadacitinib
Alomary S, Baker N, Ogunleye T, Taylor S
AAD Annual Meeting 2026Denver, 27–31 Mar 2026 · published in JAAD 6 Jul 2026
Abstract
The abstract’s text is on the JAAD website.
DOI 10.1016/j.jaad.2026.04.1375 · Not in PubMed: details from Crossref